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A bs tr ac t
Background
Implantable cardioverter–defibrillators (ICDs) prevent sudden death from cardiac caus­
es in selected patients but require the use of transvenous lead systems. To eliminate the 
need for venous access, we designed and tested an entirely subcutaneous ICD system.
Methods
First, we conducted two short­term clinical trials to identify a suitable device con­
figuration and assess energy requirements. We evaluated four subcutaneous ICD 
configurations in 78 patients who were candidates for ICD implantation and subse­
quently tested the best configuration in 49 additional patients to determine the sub­
cutaneous defibrillation thresh old in comparison with that of the standard trans­
venous ICD. Then we evaluated the long­term use of subcutaneous ICDs in a pilot 
study, involving 6 patients, which was followed by a trial involving 55 patients.
Results
The best device configuration consisted of a parasternal electrode and a left lateral 
thoracic pulse generator. This configuration was as effective as a transvenous ICD for 
terminating induced ventricular fibrillation, albeit with a significantly higher mean 
(±SD) energy requirement (36.6±19.8 J vs. 11.1±8.5 J). Among patients who received a 
permanent subcutaneous ICD, ventricular fibrillation was successfully detected in 
100% of 137 induced episodes. Induced ventricular fibrillation was converted twice in 
58 of 59 patients (98%) with the delivery of 65­J shocks in two consecutive tests. 
Clinically significant adverse events included two pocket infections and four lead revi­
sions. After a mean of 10±1 months, the device had successfully detected and treated 
all 12 episodes of spontaneous, sustained ventricular tachyarrhythmia.
Conclusions
In small, nonrandomized studies, an entirely subcutaneous ICD consistently detected 
and converted ventricular fibrillation induced during electrophysiological testing. 
The device also successfully detected and treated all 12 episodes of spontaneous, 
sustained ventricular tachyarrhythmia. (ClinicalTrials.gov numbers, NCT00399217 
and NCT00853645.)
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The use of implantable cardioverter–defibrillators (ICDs) is an established ther­apy for the prevention of death from ven­
tricular arrhythmia.1-5 However, conventional ICDs 
rely on transvenous leads for cardiac sensing and 
defibrillation. Complications of defibrillator im­
plantation have been associated mainly with 
transvenous lead insertion and have included 
pneumothorax, hemothorax, and cardiac tampon­
ade.6-10 Difficulties in achieving venous access can 
prolong the procedure and occasionally result in 
failed ICD implantation.11-13 In the long term, lead 
failure remains a major limitation in the use of 
ICDs, despite decades of innovations in lead de­
sign.12-22 Lead failure either generates inappropri­
ate shocks or impedes appropriate therapy.20-23 
Moreover, failed leads often require removal, a pro­
cedure that is associated with substantial mor­
bidity and mortality.24-36 If cardiac pacing is not 
necessary, there may be a clinical advantage in 
avoiding the use of transvenous electrodes. In this 
report, we describe the initial evaluation of an en­
tirely subcutaneous ICD system designed to avoid 
the need for the placement of sensing and therapy 
electrodes within or on the heart.
Me thods
Study Design
We report the results of two short­term trials of a 
temporarily inserted subcutaneous ICD electrode 
system, followed by two trials of long­term sub­
cutaneous ICD implantation of a fully functional 
system. All the studies were sponsored by the 
manufacturer of the subcutaneous ICD, Cameron 
Health, and were designed by six of the academic 
investigators. The protocols were approved by the 
ethics committee at each participating institution 
and associated national and local regulatory agen­
cies. All study participants satisfied standard cri­
teria for ICD implantation37 and provided written 
informed consent. Study data were collected by all 
the authors; device data were provided by engineers 
employed by the sponsor. The original man uscript 
was written by the first author with review and revi­
sion by all coauthors. All authors vouch for the 
accuracy and completeness of the data and the 
analyses.
Evaluation of Lead Configuration
From September 2001 through February 2004, we 
conducted the first short­term defibrillation trial 
to identify the best electrode configuration among 
those tested for the subcutaneous ICD. Four elec­
trode configurations were selected on the basis of 
the use of specific anatomical landmarks: a left 
lateral pulse generator with an 8­cm coil electrode 
positioned at the left parasternal margin, a left 
pectoral pulse generator with a 4­cm coil elec­
trode at the left inferior sternum, a left pectoral 
pulse generator with an 8­cm coil electrode curv­
ing from the left inferior sternum across to the 
inferior margin of the left sixth rib, and a left 
lateral pulse generator with a left parasternal 
5­cm2 oval disk (Fig. 1).
A total of 78 patients participated in this trial. 
Each patient underwent temporary subcutaneous 
implantation of one or more of the four device 
configurations evaluated and testing of the defi­
brillation threshold. The details of the protocol 
for defibrillation­threshold testing are described 
in the Supplementary Appendix, available with the 
full text of this article at NEJM.org. Testing was 
conducted in an interleaved fashion with the use 
of a Latin square design; the data were evaluated 
by means of analysis of variance.38,39 After comple­
tion of the study, all temporary subcutaneous de­
vices were explanted, and each patient underwent 
implantation of a conventional transvenous ICD.
Comparison of Temporary Subcutaneous ICD 
with Transvenous ICD
From April 2004 through June 2005, in a second 
short­term trial involving 49 patients, we compared 
the best of the tested subcutaneous ICD systems 
in the first short­term trial (Fig. 1A) with a trans­
venous ICD system. For each patient, both the 
subcutaneous and transvenous devices were im­
planted during the same procedure. Defibrilla­
tion thresholds were compared after both sys­
tems were in position and both surgical pockets 
had been closed. The system that was tested first 
was selected randomly. The protocol for defibril­
lation­threshold testing of the subcutaneous ICD 
was identical to that used in the first short­term 
trial, as described in the Supplementary Appen­
dix. The statistical comparison of the defibrilla­
tion thresholds for the devices was performed 
with the use of a paired t­test. After completion of 
the study, the subcutaneous device was explanted.
Permanent Implantation
After the two short­term trials, we performed two 
trials of permanent subcutaneous ICD implanta­
tion: a pilot trial involving 6 patients who under­
went implantation in July 2008 in New Zealand, 
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followed by a trial involving 55 patients who un­
derwent implantation in New Zealand and Eu­
rope between December 2008 and February 2009. 
We identified candidates for subcutaneous ICD 
implantation among the patients who were re­
ferred for ICD implantation at each participating 
center. The inclusion criterion was a class I, IIa, 
or IIb indication for ICD therapy.37 Exclusion cri­
teria were an estimated glomerular filtration rate 
of less than 30 ml per minute, a requirement for 
antibradycardia pacing, a history of ventricular 
tachycardia at rates slower than 170 beats per min­
ute, and documented ventricular tachycardia known 
to be reliably terminated with antitachycardia pac­
ing. The primary end point was successful imme­
diate conversion of two consecutive episodes of in­
duced ventricular fibrillation, each with a single 
65­J shock.
LGen-S8
A
PGen-C8
PGen-S4
LGen-S5 Disk
C
B
D
Figure 1. Four Configurations of a Subcutaneous Implantable Cardioverter–Defibrillator.
The four lead systems that were tested to select the best of these candidates were a left lateral pulse generator with an 8-cm coil elec-
trode positioned at the left parasternal margin, designated LGen-S8 (Panel A); a left pectoral pulse generator with a left parasternal 
4-cm coil electrode at the inferior sternum, designated PGen-S4 (Panel B); a left pectoral pulse generator with an 8-cm coil electrode 
curving from the left inferior parasternal line across to the inferior margin of the left sixth rib, designated PGen-C8 (Panel C); and a left 
lateral pulse generator with a left parasternal 5-cm2 oval disk, designated LGen-S5 (Panel D).
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on August 14, 2013. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
An Entirely Subcutaneous Cardioverter–Defibrillator
n engl j med 363;1 nejm.org july 1, 2010 39
Subcutaneous ICD System
The subcutaneous ICD system that we tested in 
these studies consists of a 3­mm tripolar para­
sternal electrode (polycarbonate urethane 55D), 
which is connected to an electrically active pulse 
generator. The electrode is positioned parallel to 
and 1 to 2 cm to the left of the sternal midline, and 
the pulse generator is positioned over the sixth 
rib between the midaxillary line and the anterior 
axillary line (Fig. 2). The electrode has an 8­cm 
shocking coil, flanked by two sensing electrodes. 
The distal sensing electrode is positioned adja­
cent to the manubriosternal junction, and the 
proximal sensing electrode is positioned adjacent 
to the xiphoid process. The insertion of the sub­
cutaneous ICD is guided exclusively by anatomical 
landmarks; no fluoroscopy is required. The surgi­
cal procedure and the device­testing protocol dur­
ing implantation are described in the Supplemen­
tary Appendix.
During device operation, the cardiac rhythm is 
detected by the two sensing electrodes or by either 
of the sensing electrodes and the pulse generator. 
The subcutaneous ICD system automatically se­
lects an appropriate vector for rhythm detection 
and for avoiding double QRS counting and T­wave 
oversensing. Once signals have been validated as 
free of noise and double detection, feature analy­
sis and rate detection are used to sort rhythm type 
and determine the need for therapy. A condition­
al discrimination zone incorporating a feature­
extraction technique can be programmed between 
rates of 170 and 240 beats per minute to distin­
guish supraventricular tachycardia from ventric­
ular tachycardia and avoid inappropriate treatment 
of the former. Reconfirmation of ventricular tach­
yarrhythmia follows capacitor charging to avoid 
the delivery of shocks for nonsustained ventricu­
lar tachyarrhythmias. Testing of the device during 
implantation is done with the use of 65­J shocks 
to ensure a margin of safety. However, after the 
device has been implanted, it delivers only 80­J 
shocks. It can also reverse shock polarity auto­
matically if the initial shock is not successful. In 
addition, demand pacing at 50 beats per minute 
is available for 30 seconds after a shock, with the 
use of a 200­mA biphasic transthoracic pulse. Pac­
ing is activated only after more than 3.5 seconds 
of post­shock asystole.
All device settings are automated except for 
shock therapy (on/off), pacing after a shock (on/
off), conditional discrimination of supraventricu­
lar tachycardia (on/off), and the upper­rate cutoff 
for the conditional shock zone (between 170 and 
240 beats per minute). Data storage includes pre­
event electrograms and rhythm markers through 
event termination. Up to 24 treated episodes 
can be stored, with up to 120 seconds of data per 
episode.
R esult s
Evaluation of Lead Configuration
In the study comparing four lead configurations, 
the mean (±SD) age of the 78 patients was 61±11 
years (range, 31 to 80), and 72 of the patients were 
men. The average weight was 82.4±15.2 kg (range, 
53.0 to 143.5 [182±34 lb; range, 117 to 316]). The 
mean ejection fraction was 0.35±0.14 (range, 0.10 
to 0.69). The mean defibrillation thresholds were 
32.5±17.0 J (95% confidence interval [CI], 27.8 to 
37.3) for configuration 1, 40.4±13.7 J (95% CI, 35.4 
to 45.4) for configuration 2, 40.1±14.9 J (95% CI, 
33.7 to 46.5) for configuration 3, and 34.3±12.1 J 
(95% CI, 28.8 to 39.8) for configuration 4 (Fig. 3A). 
D
P
C
Pulse
generator
Figure 2. Locations of the Components of a Subcutaneous Implantable  
Cardioverter–Defibrillator In Situ.
The distal and proximal sensing electrodes (D and P, respectively) of the 
LGen-S8 device are shown, with the left lateral pulse generator and an 8-cm 
parasternal coil electrode (C).
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The left lateral pulse generator with the 8­cm 
parasternal coil electrode (Fig. 1A) had the low­
est mean defibrillation threshold, although the 
differences among the configurations were not 
significant (P = 0.07 for all comparisons by analy­
sis of variance).
Temporary Subcutaneous ICD versus 
Transvenous ICD
In the study comparing the subcutaneous ICD 
with the transvenous ICD, the mean age of the 49 
patients was 64±11 years (range, 42 to 79), and 
47 of the patients were men. The average weight 
was 85.3±12.8 kg (range, 61.0 to 114.0 [188±28 
lb; range, 134 to 251]). The mean ejection fraction 
was 0.37±0.13 (range, 0.19 to 0.70). The mean de­
fibrillation threshold was 11.1±8.5 J (95% CI, 8.6 
to 13.5) with the transvenous ICD and 36.6±19.8 J 
(95% CI, 31.1 to 42.5) with the subcutaneous ICD 
(P<0.001) (Fig. 3B). The transvenous device in 
one patient and the subcutaneous device in an­
other patient failed to terminate induced ventric­
ular fibrillation at maximum device output. In 
the patient whose subcutaneous ICD failed defi­
brillation testing, the parasternal electrode had 
been incorrectly positioned approximately 6 cm 
to the left of the sternum, beyond the left lateral 
margin of the heart.
Permanent Subcutaneous ICD Pilot Study
Six patients requiring ICD therapy underwent per­
manent subcutaneous device implantation in the 
pilot study. The mean age of the patients was 
60±11 years (range, 46 to 72), with a mean weight 
of 99.0±12.0 kg (range, 87.0 to 114.0 [218±26 lb; 
range, 192 to 251]). All the patients were men. 
The mean ejection fraction was 0.23±0.07 (range, 
0.15 to 0.35). Five of the patients had coronary 
disease, and one had nonischemic cardiomyopa­
thy. Two had undergone previous cardiac surgery. 
One patient had a secondary­prevention indication, 
and five had a primary­prevention indication.
All six patients underwent successful implan­
tation of the subcutaneous ICD, and in all the 
patients, defibrillation with 65­J submaximal 
shocks was successful during two consecutive epi­
sodes of induced ventricular fibrillation. A total 
of 18 episodes of ventricular fibrillation were in­
duced (with one patient having multiple episodes 
of nonsustained ventricular fibrillation terminat­
ing before shock delivery); all the episodes were 
appropriately detected. After 488±2 days of fol­
low­up (95 patient­months of subcutaneous ICD 
therapy), no spontaneous episodes of ventricular 
tachycardia or ventricular fibrillation had oc­
curred in the six patients, and all were well, with 
no device­related complications or inappropri­
ate shocks. Figure 4 shows data from one patient, 
with postoperative chest radiographs and an elec­
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Figure 3. Energy Delivered with the Subcutaneous Implantable Cardiovert-
er–Defibrillator (ICD), According to Lead Configuration, and a Comparison 
of Defibrillation Thresholds in Transvenous and Subcutaneous ICDs.
Panel A shows delivered defibrillation-threshold energies (measured in 
joules) in the four practical lead configurations that are described in Figure 
1, as tested during trials of acute defibrillation ranges involving 78 patients. 
The T bars indicate standard deviations. Panel B shows a comparison of 
paired defibrillation-threshold data for transvenous ICDs and subcutane-
ous ICDs in 49 consecutive patients during randomized testing. The subcu-
taneous ICD was as effective as a transvenous ICD for terminating induced 
ventricular fibrillation, although with a significantly higher mean (±SD) en-
ergy requirement (36.6±19.8 J vs. 11.1±8.5 J, P<0.001). In these tests, the 
transvenous ICD in one patient and the subcutaneous ICD in another pa-
tient failed to defibrillate induced ventricular fibrillation at maximum device 
output. In each of these two cases, 20 J was arbitrarily added to the highest 
energy tested to assign a defibrillation-threshold value. In the patient 
whose subcutaneous device failed defibrillation testing, the parasternal 
electrode had been incorrectly placed 6 cm lateral to the sternum.
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trogram from one episode of induction and ter­
mination of ventricular fibrillation.
European Clinical Trial
For the European single­group clinical trial, 65 pa­
tients who presented for ICD implantation satis­
fied the enrollment criteria. Eight patients declined 
to participate in the study, and in two cases, the 
patient’s physician opted for implantation of a 
transvenous ICD. Thus, 55 patients were enrolled 
in the trial, and all received a subcutaneous ICD. 
The clinical characteristics of the patients are 
shown in Table 1.
Defibrillation testing was not possible in two 
patients because of intraoperative hemodynamic 
instability in one patient and failure to induce ven­
tricular fibrillation in the other. Therefore, 53 pa­
tients were evaluated for sensing and defibrillation 
during implantation. Of 137 episodes of induced 
ventricular fibrillation, 100% were detected by the 
subcutaneous ICD. In 52 of the 53 patients who 
were tested (98%), two consecutive episodes of 
induced arrhythmia were successfully converted 
at 65 J. Among these 52 patients, conversion was 
achieved with standard polarity in 50 patients and 
with reverse polarity in 2 patients. In the 53rd 
patient, defibrillation at 65 J was achieved during 
the first induction but not during the second in­
duction. As specified by the protocol, this patient 
received a transvenous ICD. In another patient, it 
was necessary to reposition the electrode, which 
was initially inserted in an inappropriate location 
6 cm from the midline. The mean time to delivery 
of a shock was 14.0±2.5 seconds. The mean dura­
tion of the procedure, which was performed for 
the first time by most of the practitioners, includ­
ing device insertion and at least two induction 
and termination tests, was 67±33 minutes. The 
procedure time was reduced to 55±23 minutes for 
practitioners who completed at least three im­
plantations.
After 10±1 months and 46 patient­years of fol­
low­up, 54 of 55 patients (98%) were alive. One 
death from renal failure occurred 6 months after 
device implantation in an 84­year­old patient. 
Eighteen days before he died, the patient request­
ed that his subcutaneous ICD be turned off. 
A pocket infection developed in two patients; 
pocket revision was performed in one patient, and 
the other elected to discontinue defibrillator ther­
apy. There were no cases of pocket erosion. No 
lead fractures developed in any patient, and no 
generator migration occurred. Minor lead migra­
tion was noted during follow­up in two patients. 
BA
C
Figure 4. Chest Radiographs and an Electrocardiogram in a Patient Who Underwent Placement and Testing  
of a Subcutaneous Implantable Cardioverter–Defibrillator (ICD).
The radiographs in Panels A and B show the locations of the electrode and pulse generator of a subcutaneous ICD 
in a 54-year-old man who was evaluated in the pilot study. Panel C shows an electrocardiogram of an episode of in-
duced ventricular fibrillation and its termination in the patient. The subcutaneous ICD was being evaluated for pri-
mary prevention in the patient, who had coronary disease, New York Heart Association class II heart failure with an 
ejection fraction of 15%, and obstructive lung disease; the patient’s weight was 92 kg (203 lb).
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Another three patients had parasternal lead dis­
lodgment due to inadequate anchoring of the 
distal tip of the electrode. In each of these pa­
tients, lead repositioning was required within a 
week after surgery. In another patient, lead dis­
lodgment occurred at 6 months, during vigorous 
physical activity.
In one patient, oversensing occurred because 
of inadequate placement of the electrode in the 
header block, resulting in inadequate contact with 
one of the sensing electrodes. This problem was 
addressed the day after surgery with reprogram­
ming of the detection vector rather than reopera­
tion. Inappropriate sensing due to muscle noise 
occurred in three patients; the problem was ad­
dressed with device reprogramming in all three 
cases. One patient who had received a new drug 
therapy had inappropriate sensing (double detec­
tion) after the narrow QRS complex in sinus 
rhythm changed to a right bundle­branch block 
during sinus tachycardia (150 beats per minute). 
During 3 months of further follow­up after the 
detection algorithm was revised, no inappropriate 
shocks occurred. No shocks were delivered inap­
propriately for atrial fibrillation, sinus tachycar­
dia, or supraventricular tachycardia at any time 
during the study when such episodes occurred at 
rates of more than 170 beats per minute.
A total of 12 episodes of spontaneous ventricu­
lar tachycardia were detected and successfully 
treated in three patients, including 1 episode 
after the above­mentioned software revisions (see 
the figure in the Supplementary Appendix). All 
patients were treated before the onset of syncope, 
and there were no adverse events. One of these 
patients was successfully treated for repetitive ven­
tricular tachycardia (“VT storm”), including seven 
successive episodes of ventricular tachycardia.
Discussion
In the studies reported here, we describe the ini­
tial evaluation of an entirely subcutaneous ICD 
system. We identified a suitable device configura­
tion, assessed the defibrillation threshold of the 
device in comparison to that of the standard trans­
venous ICD, and conducted two small, single­
group trials of permanent device implantation. 
In the permanent­implantation studies, the sub­
cutaneous ICD successfully and consistently de­
tected and converted ventricular fibrillation that 
was induced during electrophysiological testing. 
The device also successfully detected and treated 
12 episodes of spontaneous ventricular tachyar­
rhythmia that occurred in patients who were en­
rolled in the European clinical trial.
The goal of developing a subcutaneous ICD was 
to overcome some of the problems that are as­
sociated with transvenous leads in conventional 
ICDs.3,6-11,14,15,40 Such a device could potentially 
reduce or eliminate problems such as failure to 
achieve vascular access, intravascular injury, and 
lead failure requiring difficult procedures for ex­
traction and replacement. Additional potential 
benefits of such a device include the preservation 
of venous access for other uses and the avoidance 
of radiation exposure during fluoroscopy, which 
is required for transvenous ICD implantation. 
These benefits would be especially important for 
young patients, in whom leads may fail during 
the decades that therapy is needed.41
The need for ICD systems that avoid the use 
of transvenous leads has been recognized previ­
ously,42-49 and some earlier exploratory efforts led 
to the present work.50,51 Some physicians have 
adapted existing technology to treat children with 
Table 1. Clinical Characteristics of 55 Patients in the 
European Clinical Trial of a Subcutaneous Implantable 
Cardioverter–Defibrillator (ICD).*
Characteristic Value
Age — yr
Mean 56±13
Range 22–84
Male sex — no. (%) 44 (80)
Body-mass index†
Mean 28±5
Range 17–40
Left ventricular ejection fraction
Mean 0.34±0.13
Range 0.14–0.73
Cause of cardiac disease — no. (%)
Coronary artery disease 37 (67)
Nonischemic cardiomyopathy 10 (18)
Congenital heart disease 2 (4)
Other condition 6 (11)
Previous cardiac surgery — no. (%) 17 (31)
Indication for ICD — no. (%)
Primary prevention 43 (78)
Secondary prevention 12 (22)
* Plus–minus values are means ±SD.
† The body-mass index is the weight in kilograms divided 
by the square of the height in meters.
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limited venous access. Leads have been inserted 
in unusual locations, and epicardial and subcuta­
neous leads have been used.44-46 Other subcuta­
neous defibrillation systems have been shown to 
work with an approximate tripling of the energy 
that is required by a transvenous system, find­
ings that are consistent with the results of our 
study.47,48 However, such systems have not incor­
porated subcutaneous rhythm detection but in­
stead have used transvenous or epicardial sensing 
electrodes for detection.
Our studies are preliminary, early­phase trials 
that were primarily intended to show the feasibil­
ity of an entirely subcutaneous ICD. They pro­
vide limited information regarding the detection 
and conversion of ventricular tachyarrhythmia in 
the clinical setting, despite the demonstration of 
consistent detection and termination of ventricu­
lar fibrillation at the time of implantation. These 
studies cannot show whether subcutaneous ICDs 
are superior to conventional transvenous ICDs 
with respect to such characteristics as lead sta­
bility or failure. Indeed, the initial experience in­
cludes several cases of problems such as lead 
migration, lead dislodgment, and inappropriate 
sensing. With respect to each of these issues, the 
subcutaneous ICD system was adjusted shortly af­
ter implantation in an effort to improve the sys­
tem’s reliability. Problems with lead dislodgment 
have led to the introduction of an anchoring 
sleeve and a new surgical technique. Inappropri­
ate sensing has been addressed through software 
revision, with no incidents in the 3 months after 
revision. However, these modifications will require 
further testing in additional groups of patients. 
Ultimately, the relative benefit of subcutaneous 
ICDs, as compared with transvenous ICDs, will 
need to be shown in large, long­term, random­
ized, prospective, multicenter clinical trials.
In addition, there are inherent limitations of 
this device design. Although transient post­shock 
pacing is available, the subcutaneous ICD cannot 
provide long­term pacing. It is therefore not an 
alternative to transvenous ICDs when antibrady­
cardia pacing is required. Also, the subcutaneous 
ICD is not designed to treat patients with ventricu­
lar tachycardia at rates slower than 170 beats per 
minute. The lack of capability to provide anti­
tachycardia pacing may be a limitation in patients 
with frequent, recurrent, monomorphic ventricu­
lar tachycardia.
In conclusion, we found that in small, nonran­
domized studies, an entirely subcutaneous ICD 
system successfully and consistently detected and 
converted episodes of ventricular fibrillation that 
were induced during electrophysiological testing. 
It also successfully detected and treated all 12 
episodes of spontaneous, sustained ventricular 
tachy arrhythmia.
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